HCW BiologicsHCWB
13F holders, Q4 2025 (December 31)14holders +4
5new positions
1sold out
1famous investor
$0.97avg. 13F price*
At the end of Q4 2025, 14 institutions reported holding HCW Biologics Inc. (HCWB) in their 13F filings, up 4 from Q3 2025. 5 opened new positions and 1 sold out. The largest holders were Armistice Capital, LLC ($291K), DRW Securities, LLC ($34K) and Citadel Advisors ($22K). One famous investor held it Ken Griffin (0.0% of Citadel Advisors's portfolio).
- Company
- HCW Biologics Inc.
- CUSIP
- 40423R204
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 5 | $346K |
| Exits | 1 | $4 |
All 13F filers, Q3 2025 → Q4 2025: 362,627 shares bought and 49,166 shares sold, net +313,461 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 14 holders
| Armistice Capital, LLC | 0.01% | New | 300,180 | $291K |
| DRW Securities, LLC | 0.00% | Reduce -57.7% | 35,281 | $34K |
| Citadel Advisors | 0.00% | New | 22,158 | $22K |
| Susquehanna International Group, LLP | 0.00% | New | 20,071 | $19K |
| Vanguard Group Inc. | 0.00% | No change | 15,426 | $15K |
| Geode Capital Management, LLC | 0.00% | Add +27.6% | 14,037 | $14K |
| J.W. Cole Advisors, Inc. | 0.00% | New | 12,500 | $12K |
| Golden State Wealth Management, LLC | 0.00% | No change | 10,000 | $10K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +188.3% | 4,504 | $4K |
| UBS Group AG | 0.00% | New | 1,739 | $2K |
| Wells Fargo & Company | 0.00% | Reduce -41.2% | 1,000 | $971 |
| Osaic Holdings, Inc. | 0.00% | No change | 26 | $25 |
| Bank of America Corp. | 0.00% | Add +10.0% | 11 | $11 |
| Citigroup Inc. | 0.00% | Reduce -99.7% | 1 | $1 |
"% of holder's portfolio" is HCWB's weight in each manager's 13F, not the share of HCW Biologics Inc. the manager owns.